Global Hematologic Malignancies Market Outlook To 2025: Key Disease Type (Leukemia, Non-Hodgkin Lymphoma, Hodgkin Lymphoma, Multiple Myeloma), Treatment Categories (Chemotherapy, Radiation therapy, Immunotherapy, Stem Cell Transplantation), Drug Class (Antineoplastic agent, Chemotherapy, Kinase Inhibitor, Others), Distribution Channel (Hospitals, Drug Store, Specialty Pharmacy, E-Pharmacy), Regional Segmentation, Competitive Dynamics, M&A Insights, Pricing Analysis (OPP, IPP, RAP), And Segment Forecast

$3,650.00$6,650.00

Clear
  • Report Description
  • Table of Content
  • Highlight
  • Research Methodology
  • Request Free Sample

The global Hematologic Malignancies market was valued at $42.8 Billion in 2017 and is forecast to grow at a modest XX.2 % CAGR between 2018 and 2025, culminating in 2025 global sales of $67.5 Billion.

 

There are no definitive causes for hematologic malignancies. These cells in hematologic cancers arise from types of white blood cells: lymphocytes, granulocytes, and plasma cells. Approximately one in every 3 minutes diagnosed with a blood cancer in U.S. 174,250 people in the US are expected to be diagnosed with leukemia, lymphoma or myeloma in 2018. New cases of leukemia, lymphoma, and myeloma are expected to account for 10 percent of the estimated 1,735,350 new cancer cases diagnosed in the US in 2018.

 

On an average every 9 minutes or 6 people every hour, in the US dies from a blood cancer. Leukemia, lymphoma, and myeloma are expected to cause the deaths of an estimated 58,100 people in the US in 2018. These account for 9.5 percent of the total deaths from cancer in 2018, based on the estimated total of 609,640 cancer deaths.

 

Global Hematologic Malignancies Market Outlook To 2025

Pricing Analysis

 

“Optimal Price Point (OPP) for Hematologic Malignancies Products”

 

Estimated Average product/ service cost – $ xx globally. However, with improving access and availability of options, OPP and range of acceptable Prices (RAP) are going to change. We at Ameri Research continuously track these prices with our proprietary pricing model.

 

Due to the wide array of products available in the market, pricing, positioning, and sales channel optimization play a vital role in the success of a product. On an average, in the U.S., the blood cancer drugs are available at USD xxx- USD xxxx. However, the high-end products are available at much higher prices. The prices in emerging countries and developed countries vary significantly due to the difference in purchasing power and availability of latest products.

 

Hematologic Malignancies Market by “Disease Type”

 

We have segmented the hematologic malignancies market into Leukemia, Non-Hodgkin Lymphoma, Hodgkin Lymphoma, Multiple Myeloma. Leukemia involves the creation of abnormal white blood cells (WBC’s). There is a different type of Leukemia as acute lymphocytic leukemia (ALL), acute myelogenous leukemia (AML), chronic lymphocytic leukemia (CLL), and chronic myelogenous leukemia (CML). Lymphoma is the type of hematologic malignancies involving lymphatic system. The major difference between Non-Hodgkin and Hodgkin lymphoma are Reed-Sternberg cells. Myeloma is hematologic malignancies in plasma cells help to create antibodies. We are observing a steep rise in Leukemia during forecasting period.

 

Hematologic Malignancies Market by “Treatment Categories”

 

We have segmented the hematologic malignancies market by treatment into Chemotherapy, Radiation therapy, Immunotherapy and Stem Cell Transplantation. We are observing newer biologic into immunotherapy shaping the hematologic malignancies. Advancing novel therapeutic agents for the treatment of malignancy proving costly and lengthy process. Cost estimates for de novo drug discovery range from $500 million to $2 billion.

 

Hematologic Malignancies Market by “Drug Class”

 

We have broadly segmented the market as Antineoplastic agent, Chemotherapy, Kinase Inhibitor and Others. Some of the major drugs, we have classified as Antineoplastic agent (Rituxan, Gleevec, Revlimid, Pomalyst, Vidaza, Kyprolis, Adcetris), Chemotherapy (Velcade), Kinase Inhibitor (Tasigna). Gleevec reported sales of USD 448 million in 2017.

 

Hematologic Malignancies Market by “Distribution Channel”

 

We have segmented the market based on distribution channel as Hospitals, Drug Store, Specialty Pharmacy, E-Pharmacy. Majority of products channelized through hospitals (Particularly Chemo, Surgery and Radiation). However, we are observing the increased role of specialized pharmacy and E-pharmacy in the distribution/ dispensation of treatment drugs. Patient education to increase compliance and Persistency plays a key role in the outcome. Many payors are linking reimbursement to the outcome.

 

Regional Segmentation

 

North America accounted for the maximum revenue share of over 40% in 2017 due to increased patient number, lifestyle followed by availability of treatment options, better reimbursement plan, and RND.  Followed by EU- Top 5 countries contribute $X.6 Billion in 2017 and expected to reach $x.5 Billion by 2023.

With changing lifestyle in developing countries and availability of treatment option, we are observing a rise in patient numbers in developing countries. However, these markets represent a minuscule percentage of the overall market.

 

“Competitive Landscape” and “Merger & Acquisition Insights”

 

The key market participants include Pfizer Inc., Novartis AG, F. Hoffmann-LA Roche Ltd, Celgene, Sanofi-Aventis, Bristol-Myers Squibb Company, AbbVie, GlaxoSmithKline, Amgen, Johnson & Johnson, and Takeda Pharmaceutical Company Limited. The growing investment in research and development is driving the companies to innovate, stay market relevant and retain their share. Moreover, there are several startup companies working on stem cell and biologic research, and these companies are considered as strategic assets for merger and acquisition. Some of the most notable transactions in the recent past include,

  • Amgen to Acquire Micromet, which is working on a Novel Cancer Treatment in Clinical Trials for Hematologic Malignancies.
  • Celgene reportedly in talks to buy CAR-T cell therapy firm.

 

 

Market Segmentation

 

Hematologic Malignancies Market by Disease Type (Revenue, Million, 2014 – 2025)

  • Leukemia
    • Acute Lymphocytic Leukemia
    • Chronic Lymphocytic Leukemia
    • Acute Myeloid Leukemia
    • Chronic Myeloid Leukemia
  • Non-Hodgkin Lymphoma
    • B-cell Lymphoma
      • Diffuse Large B-Cell Lymphoma
      • Mantle Cell Lymphoma
      • Burkitt Lymphoma
      • Central Nervous System Lymphoma
    • T-cell Lymphoma
      • Precursor T-Lymphoblastic Lymphoma
      • Peripheral T-Lymphoma
    • Hodgkin Lymphoma
    • Multiple Myeloma

 

Hematologic Malignancies Market by Treatment Categories (Revenue, Million, 2014 – 2025)

  • Chemotherapy
  • Radiation therapy
  • Immunotherapy
  • Stem Cell Transplantation

 

Hematologic Malignancies Market by Drug Class (Revenue, Million, 2014 – 2025)

  • Antineoplastic agent (Glivec, Revlimid (Lenalidomide), Pomalyst (Pomalidomide) Vidaza (Azacitidine) Kyprolis (Carfilzomib) Adcetris (Brentuximab Vedotin))
  • Chemotherapy (Velcade (Bortezomib)
  • Kinase Inhibitor (Tasigna (Nilotinib))

 

Hematologic Malignancies Market by Distribution Channel (Revenue, Million, 2014 – 2025)

  • Hospitals
  • Drug Store
  • Specialty Pharmacy
  • E-Pharmacy

 

Hematologic Malignancies Market Regional Outlook (Revenue, USD Million, 2014- 2025)

 

  • North America
    • U.S.
    • Canada
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
  • Asia Pacific
    • Japan
    • China
    • India
  • Latin America
    • Brazil
    • Mexico
    • Columbia
  • Middle East and Africa
    • South Africa
    • Saudi Arabia

 

Hematologic Malignancies Market, Hematologic Malignancies Market Analytics, Hematologic Malignancies Market Share, Hematologic Malignancies Market Research, Hematologic Malignancies Market Forecast, Hematologic Malignancies Market Insight, Hematologic Malignancies Market Trend, Hematologic Malignancies Market Value,Hematologic Malignancies Market Size, Hematologic Malignancies Market Analysis, Hematologic Malignancies Market Survey, Blood Cancer Drugs Market, Blood Cancer Drugs Market Analytics, Blood Cancer Drugs Market Share, Blood Cancer Drugs Market Research, Blood Cancer Drugs Market Forecast, Blood Cancer Drugs Market Insight, Blood Cancer Drugs Market Trend, Blood Cancer Drugs Market Value,Blood Cancer Drugs Market Size, Blood Cancer Drugs Market Analysis, Blood Cancer Drugs Market Survey

Chapter 1 Methodology and Scope

  • Research Methodology
  • Research Scope & Assumptions
  • List of Data Sources

Chapter 2 Executive Summary

Chapter 3 Hematologic Malignancies Market Overview

  • Global Disease Landscape
  • Global Healthcare Expenditure

Chapter 4 Hematologic Malignancies Industry Outlook

  • Market Overview
  • Market Segmentation
  • Market Size and Growth Prospects
  • Leading Brand Dynamics
  • Key Market Drivers
    • Increasing patient base
    • Investment by Large Pharma for cancer research
    • Robust product pipeline
    • Increasing Collaboration
    • Increased diagnosis and early detection
    • Technological Advancements and newer drug approval
  • Key Market Challenges
    • Access barrier to high-cost drugs
    • Serious side effect to Cancer Drugs
    • Lack of Awareness and reimbursement plans in Emerging Countries
  • Key Opportunities Prioritized
  • Industry Analysis - Porter’s
  • Hematologic Malignancies Market-PESTEL Analysis

Chapter 5: - Hematologic Malignancies Market by “Disease Type” (USD Million)

  • Hematologic Malignancies Market Landscape by Disease Type- 2017 & 2025
    • Leukemia
  • Market Landscape Analysis, 2017-2025
    • Acute Lymphocytic Leukemia
  • Market Landscape Analysis, 2017-2025
    • Chronic Lymphocytic Leukemia
  • Market Landscape Analysis, 2017-2025
    • Acute Myeloid Leukemia
  • Market Landscape Analysis, 2017-2025
    • Chronic Myeloid Leukemia
  • Market Landscape Analysis, 2017-2025
    • Non-Hodgkin Lymphoma
  • Market Landscape Analysis, 2017-2025
    • B-cell Lymphoma
  • Market Landscape Analysis, 2017-2025
    • Diffuse Large B-Cell Lymphoma
  • Market Landscape Analysis, 2017-2025
    • Mantle Cell Lymphoma
  • Market Landscape Analysis, 2017-2025
    • Burkitt Lymphoma
  • Market Landscape Analysis, 2017-2025
    • Central Nervous System Lymphoma
  • Market Landscape Analysis, 2017-2025
    • T-cell Lymphoma
  • Market Landscape Analysis, 2017-2025
    • Precursor T-Lymphoblastic Lymphoma
  • Market Landscape Analysis, 2017-2025
    • Peripheral T-Lymphoma
  • Market Landscape Analysis, 2017-2025
    • Hodgkin Lymphoma
  • Market Landscape Analysis, 2017-2025
    • Multiple Myeloma
  • Market Landscape Analysis, 2017-2025
 

Chapter 5: - Hematologic Malignancies Market by “Treatment Categories” (USD Million)

  • Hematologic Malignancies Market Landscape by Treatment Categories- 2017 & 2025
    • Chemotherapy
  • Market Landscape Analysis, 2017-2025
    • Radiation therapy
  • Market Landscape Analysis, 2017-2025
    • Immunotherapy
  • Market Landscape Analysis, 2017-2025
    • Stem Cell Transplantation
  • Market Landscape Analysis, 2017-2025

Chapter 6: - Hematologic Malignancies Market by “Drug Class” (USD Million)

  • Hematologic Malignancies Market Landscape by Drug Class- 2017 & 2025
    • Antineoplastic Agent
      • Market Landscape Analysis, 2017-2025
    • Chemotherapy
      • Market Landscape Analysis, 2017-2025
    • Kinase Inhibitors
      • Market Landscape Analysis, 2017-2025

Chapter 7: - Hematologic Malignancies Market by “Distribution Channel” (USD Million)

  • Hematologic Malignancies Market Landscape by Distribution Channel- 2017 & 2025
    • Hospitals
      • Market Landscape Analysis, 2017-2025
    • Drug Store
      • Market Landscape Analysis, 2017-2025
    • Specialty Pharmacy
      • Market Landscape Analysis, 2017-2025
    • E-Pharmacy
      • Market Landscape Analysis, 2017-2025

Chapter 10: Regional Market Outlook

Hematologic Malignancies Market Landscape by Region- 2017
  • North America Market Landscape Analysis, 2017-2025 (USD Mn)
    • U.S. Market Landscape Analysis, 2017-2025
    • Canada Market Landscape Analysis-2017-2025
  • Europe Market Landscape Analysis, 2017-2025 (USD Mn)
    • UK Market Landscape Analysis, 2017-2025
    • Germany Market Landscape Analysis, 2017-2025
    • France Market Landscape Analysis, 2017-2025
    • Italy Market Landscape Analysis, 2017-2025
    • Spain Market Landscape Analysis, 2017-2025
  • Latin America Market Landscape Analysis, 2017-2025 (USD Mn)
    • Brazil Market Landscape Analysis, 2017-2025
    • Mexico Market Landscape Analysis, 2017-2025
    • Colombia Market Landscape Analysis, 2017-2025
  • Asia Pacific Market Landscape Analysis, 2017-2025 (USD Mn)
    • Japan Market Landscape Analysis, 2017-2025
    • China Market Landscape Analysis, 2017-2025
    • India Market Landscape Analysis, 2017-2025
    • Australia Market Landscape Analysis, 2017-2025
  • Middle East & Africa Market Landscape Analysis, 2014-2025 (USD Mn)
    • Saudi Arabia Market Landscape Analysis, 2014-2025
    • South Africa Market Landscape Analysis, 2014-2025
 

Chapter 11: Pricing Analysis

  Optimal Price Points (OPP), Indifference price points (IPP) and Range of Acceptable Prices and (RAP) of leading brands by Region- 2017
  • North America Pricing Analysis (OPP, IPP, and RAP - 2017)
    • U.S. Pricing Analysis-2017
    • Canada Pricing Analysis-2017
  • Europe Pricing Analysis (OPP, IPP, and RAP - 2017)
    • UK Pricing Analysis-2017
    • Germany Pricing Analysis-2017
    • France Pricing Analysis-2017
    • Italy Pricing Analysis-2017
    • Spain Pricing Analysis-2017
  • Latin America Pricing Analysis (OPP, IPP, and RAP - 2017)
    • Brazil Pricing Analysis-2017
    • Mexico Pricing Analysis-2017
    • Colombia Pricing Analysis-2017
  • Asia Pacific Pricing Analysis (OPP, IPP, and RAP - 2017)
    • Japan Pricing Analysis-2017
    • China Pricing Analysis-2017
    • India Pricing Analysis-2017
  • Middle East Pricing Analysis (OPP, IPP, and RAP - 2017)
    • Saudi Arabia Pricing Analysis-2017
    • South Africa Pricing Analysis-2017

Chapter 12: Hematologic Malignancies Pipeline Analysis

  • Executive Summary
  • Late Stage Pipeline analysis
  • Key R&D trends

Chapter 13: Hematologic Malignancies Merger & Acquisition Outlook

  • Factors driving M&A in Hematologic Malignancies market
  • Key trends and future outlook

Chapter 14: Competitive Landscape

  • Pfizer Inc.
    • Company Overview
    • Financial Performance
    • Key Decision Maker
    • Product Pipeline
    • Strategic Initiative
  • Novartis AG
    • Company Overview
    • Financial Performance
    • Key Decision Maker
    • Product Pipeline
    • Strategic Initiative
  • Hoffmann-La Roche Ltd
    • Company Overview
    • Financial Performance
    • Key Decision Maker
    • Product Pipeline
    • Strategic Initiative
  • Celgene
    • Company Overview
    • Financial Performance
    • Key Decision Maker
    • Product Pipeline
    • Strategic Initiative
  • Sanofi-Aventis
    • Company Overview
    • Financial Performance
    • Key Decision Maker
    • Product Pipeline
    • Strategic Initiative
  • GlaxoSmithKline
    • Company Overview
    • Financial Performance
    • Key Decision Maker
    • Product Pipeline
    • Strategic Initiative
  • AbbVie
    • Company Overview
    • Financial Performance
    • Key Decision Maker
    • Product Pipeline
    • Strategic Initiative
  • Amgen
    • Company Overview
    • Financial Performance
    • Key Decision Maker
    • Product Pipeline
    • Strategic Initiative
  • Bristol-Myers Squibb Company
    • Company Overview
    • Financial Performance
    • Key Decision Maker
    • Product Pipeline
    • Strategic Initiative
  • Johnson & Johnson
    • Company Overview
    • Financial Performance
    • Key Decision Maker
    • Product Pipeline
    • Strategic Initiative
  • Takeda Pharmaceutical
    • Company Overview
    • Financial Performance
    • Key Decision Maker
    • Product Pipeline
    • Strategic Initiative
   

List of Tables

 
  • TABLE 1 Hematologic Malignancies Market - Industry Snapshot & Key Buying Criteria, 2014 - 2025
  • TABLE 2 Global Hematologic Malignancies Market, 2014 – 2025
  • TABLE 3 Global Hematologic Malignancies Market Analysis by Product-2017
  • TABLE 4 Global Hematologic Malignancies Market Analysis by Technology -2017
  • TABLE 5 Global Hematologic Malignancies Market Analysis by Application-2017
  • TABLE 7 Global Hematologic Malignancies Market Analysis by Geography-2017
  • TABLE 8 Global Hematologic Malignancies Market Analysis by Leading Brands-2017
  • TABLE 9 Hematologic Malignancies Market - Key market driver analysis
  • TABLE 10 Hematologic Malignancies Market - Key market restraint analysis
  • TABLE 11 North America Market Hematologic Malignancies Landscape Analysis, 2017-2025 (USD Mn)
  • TABLE 12U.S. Hematologic Malignancies Market Landscape Analysis, 2017-2025
  • TABLE 13 Canada Hematologic Malignancies Market Landscape Analysis, 2017-2025
  • TABLE 14 Europe Hematologic Malignancies Market Landscape Analysis, 2017-2025 (USD Mn)
  • TABLE 15 U.K Hematologic Malignancies Market Landscape Analysis, 2017-2025
  • TABLE 16 Germany Hematologic Malignancies Market Landscape Analysis, 2017-2025
  • TABLE 17 France Hematologic Malignancies Market Landscape Analysis, 2017-2025
  • TABLE 18 Italy Hematologic Malignancies Market Landscape Analysis, 2017-2025
  • TABLE 19 Spain Hematologic Malignancies Market Landscape Analysis, 2017-2025
  • TABLE 20 Latin America Hematologic Malignancies Market Landscape Analysis, 2017-2025 (USD Mn)
  • TABLE 21 Brazil Hematologic Malignancies Market Landscape Analysis, 2017-2025
  • TABLE 22 Mexico Hematologic Malignancies Market Landscape Analysis, 2017-2025
  • TABLE 20 Colombia Hematologic Malignancies Market Landscape Analysis, 2017-2025
  • TABLE 21 Asia Pacific Hematologic Malignancies Market Landscape Analysis, 2017-2025 (USD Mn)
  • TABLE 22 Japan Hematologic Malignancies Market Landscape Analysis, 2017-2025
  • TABLE 23 China Hematologic Malignancies Market Landscape Analysis, 2017-2025
  • TABLE 24 India Hematologic Malignancies Market Landscape Analysis, 2017-2025
  • TABLE 25 North America Pricing Analysis
  • TABLE 26 North America Pricing Analysis (OPP, IPP, and RAP- 2017)
  • TABLE 27 U.S. Pricing Analysis-2017
  • TABLE 28 Canada Pricing Analysis-2017
  • TABLE 29 Europe Pricing Analysis (OPP, IPP, and RAP- 2017)
  • TABLE 30 U.K Pricing Analysis-2017
  • TABLE 31 Germany Pricing Analysis-2017
  • TABLE 32 France Pricing Analysis-2017
  • TABLE 33 Italy Pricing Analysis-2017
  • TABLE 34 Spain Pricing Analysis-2017
  • TABLE 35 Latin America Pricing Analysis (OPP, IPP, and RAP- 2017)
  • TABLE 36 Brazil Pricing Analysis-2017
  • TABLE 37 Mexico Pricing Analysis-2017
  • TABLE 38 Colombia Pricing Analysis-2017
  • TABLE 39 Asia Pacific Pricing Analysis (OPP, IPP, and RAP- 2017)
  • TABLE 40 Japan Pricing Analysis-2017
  • TABLE 41 China Pricing Analysis-2017
  • TABLE 42 India Pricing Analysis-2017
  • TABLE 43 Middle East Pricing Analysis (OPP, IPP, and RAP- 2017)
  • TABLE 44 Saudi Arabia Pricing Analysis-2017
  • TABLE 45 South Africa Pricing Analysis-2017
 

List of Figures

 
  • 1 Hematologic Malignancies Market Segmentation
  • 2 Market Size & Growth Prospects
  • 3 Leading Brand Dynamics
  • 4 Penetration & Growth Prospects
  • 5 Industry Analysis – Porter’s
  • 6 Hematologic Malignancies Market – PESTEL Analysis
  • 7 Hematologic Malignancies Market Share by Product Type, 2017 & 2025
  • 7 Hematologic Malignancies Market Share by Cell Type, 2017 & 2025
  • 7 Hematologic Malignancies Market Share by Technique, 2017 & 2025
  • 7 Hematologic Malignancies Market Share by Application, 2017 & 2025
  • 7 Hematologic Malignancies Market Share by End-Use, 2017 & 2025
  • 10 Hematologic Malignancies Market Share by Region, 2017 & 2025

Key Insights Addressed:  

  • Defining market size from 2014 to 2017.
  • Estimating market growth till 2025 and consequence market forecast.
  • Identifying market drivers, restraints & future opportunities and allowing decision-maker with a range of possible outcomes and the probabilities that will occur for any choice of action.
  • Market segments and regions that will drive or lead market growth.
  • Defining Optimal Price Point (OPP) which will be accepted and recommended by maximum customers.
  • A bird’s-eye view of competitive landscape and the key market players.
  • Key strategic growth driver adopted by market players. In-depth analysis of their strategies and implication on competition & growth.
    Key Findings:  
  • The global Hematologic Malignancies market was valued at $42.8 Billion in 2017 and is forecast to grow at a modest XX.2 % CAGR between 2018 and 2025, culminating in 2025 global sales of $67.5 Billion.
  • On an average every 9 minutes or 6 people every hour, in the US dies from a blood cancer. Leukemia, lymphoma, and myeloma are expected to cause the deaths of an estimated 58,100 people in the US in 2018. These account for 9.5 percent of the total deaths from cancer in 2018, based on the estimated total of 609,640 cancer deaths.
  • We have segmented the hematologic malignancies market into Leukemia, Non-Hodgkin Lymphoma, Hodgkin Lymphoma, Multiple Myeloma.
  • The key market participants include Pfizer Inc., Novartis AG, F. Hoffmann-LA Roche Ltd, Celgene, Sanofi-Aventis, Bristol-Myers Squibb Company, AbbVie, GlaxoSmithKline, Amgen, Johnson & Johnson, and Takeda Pharmaceutical Company Limited.

Ameri Research implies a unique methodology of published information and primary research to bring key insights to customer decision making process. Our analytics model helps us to understand the structured and unstructured information from various sources. Key steps involves in the process are as below-

    1. Analyzing Published Information- Access to large pool of paid and unpaid published information via different sources and analyzing market trend.
    2. Setting Foundation- Input from analysis of secondary sources set our foundation to market analysis and helps in setting the scope for further research. Setting the scope involves Ameri Research proprietary statistical model, discussion with industry leaders, internal brainstorming, key discussion pointers from various forums etc.
    3. Need Gap Analysis- Defining the gap between our scope and availability of information.
    4. KOL Panel Discussion- Focused Group Discussion with a structured discussion guide to fine tune the gap and deriving the factors driving/restraining the market trend.
    5. Quantitative Research- Sampling large number of industry players, Education/Research Institutes, Government bodies, NGOs, Individual acclaimed researchers and conducting the primary interview with a structured questionnaire.
    6. Data Triangulation- We apply bottom-up demand approach or top-down estimation or a combined approach to triangulate the data points.
    7. Analyst Comment- Each of our analysts carries large pool of experience from domain perspective and add their value which is directional in nature
global-aesthetic-dermatology-market

To request a free sample copy of this report, please complete the form below verified and secure

We offer complete free customization that addresses client’s need. This includes insights from primary market research and a 60-minute free analyst consultation post report purchase.

This website is secure and your personal details are safe. Privacy policy

Description

The global Hematologic Malignancies market was valued at $42.8 Billion in 2017 and is forecast to grow at a modest XX.2 % CAGR between 2018 and 2025, culminating in 2025 global sales of $67.5 Billion.

 

There are no definitive causes for hematologic malignancies. These cells in hematologic cancers arise from types of white blood cells: lymphocytes, granulocytes, and plasma cells. Approximately one in every 3 minutes diagnosed with a blood cancer in U.S. 174,250 people in the US are expected to be diagnosed with leukemia, lymphoma or myeloma in 2018. New cases of leukemia, lymphoma, and myeloma are expected to account for 10 percent of the estimated 1,735,350 new cancer cases diagnosed in the US in 2018.

 

On an average every 9 minutes or 6 people every hour, in the US dies from a blood cancer. Leukemia, lymphoma, and myeloma are expected to cause the deaths of an estimated 58,100 people in the US in 2018. These account for 9.5 percent of the total deaths from cancer in 2018, based on the estimated total of 609,640 cancer deaths.

 

Global Hematologic Malignancies Market Outlook To 2025

Pricing Analysis

 

“Optimal Price Point (OPP) for Hematologic Malignancies Products”

 

Estimated Average product/ service cost – $ xx globally. However, with improving access and availability of options, OPP and range of acceptable Prices (RAP) are going to change. We at Ameri Research continuously track these prices with our proprietary pricing model.

 

Due to the wide array of products available in the market, pricing, positioning, and sales channel optimization play a vital role in the success of a product. On an average, in the U.S., the blood cancer drugs are available at USD xxx- USD xxxx. However, the high-end products are available at much higher prices. The prices in emerging countries and developed countries vary significantly due to the difference in purchasing power and availability of latest products.

 

Hematologic Malignancies Market by “Disease Type”

 

We have segmented the hematologic malignancies market into Leukemia, Non-Hodgkin Lymphoma, Hodgkin Lymphoma, Multiple Myeloma. Leukemia involves the creation of abnormal white blood cells (WBC’s). There is a different type of Leukemia as acute lymphocytic leukemia (ALL), acute myelogenous leukemia (AML), chronic lymphocytic leukemia (CLL), and chronic myelogenous leukemia (CML). Lymphoma is the type of hematologic malignancies involving lymphatic system. The major difference between Non-Hodgkin and Hodgkin lymphoma are Reed-Sternberg cells. Myeloma is hematologic malignancies in plasma cells help to create antibodies. We are observing a steep rise in Leukemia during forecasting period.

 

Hematologic Malignancies Market by “Treatment Categories”

 

We have segmented the hematologic malignancies market by treatment into Chemotherapy, Radiation therapy, Immunotherapy and Stem Cell Transplantation. We are observing newer biologic into immunotherapy shaping the hematologic malignancies. Advancing novel therapeutic agents for the treatment of malignancy proving costly and lengthy process. Cost estimates for de novo drug discovery range from $500 million to $2 billion.

 

Hematologic Malignancies Market by “Drug Class”

 

We have broadly segmented the market as Antineoplastic agent, Chemotherapy, Kinase Inhibitor and Others. Some of the major drugs, we have classified as Antineoplastic agent (Rituxan, Gleevec, Revlimid, Pomalyst, Vidaza, Kyprolis, Adcetris), Chemotherapy (Velcade), Kinase Inhibitor (Tasigna). Gleevec reported sales of USD 448 million in 2017.

 

Hematologic Malignancies Market by “Distribution Channel”

 

We have segmented the market based on distribution channel as Hospitals, Drug Store, Specialty Pharmacy, E-Pharmacy. Majority of products channelized through hospitals (Particularly Chemo, Surgery and Radiation). However, we are observing the increased role of specialized pharmacy and E-pharmacy in the distribution/ dispensation of treatment drugs. Patient education to increase compliance and Persistency plays a key role in the outcome. Many payors are linking reimbursement to the outcome.

 

Regional Segmentation

 

North America accounted for the maximum revenue share of over 40% in 2017 due to increased patient number, lifestyle followed by availability of treatment options, better reimbursement plan, and RND.  Followed by EU- Top 5 countries contribute $X.6 Billion in 2017 and expected to reach $x.5 Billion by 2023.

With changing lifestyle in developing countries and availability of treatment option, we are observing a rise in patient numbers in developing countries. However, these markets represent a minuscule percentage of the overall market.

 

“Competitive Landscape” and “Merger & Acquisition Insights”

 

The key market participants include Pfizer Inc., Novartis AG, F. Hoffmann-LA Roche Ltd, Celgene, Sanofi-Aventis, Bristol-Myers Squibb Company, AbbVie, GlaxoSmithKline, Amgen, Johnson & Johnson, and Takeda Pharmaceutical Company Limited. The growing investment in research and development is driving the companies to innovate, stay market relevant and retain their share. Moreover, there are several startup companies working on stem cell and biologic research, and these companies are considered as strategic assets for merger and acquisition. Some of the most notable transactions in the recent past include,

  • Amgen to Acquire Micromet, which is working on a Novel Cancer Treatment in Clinical Trials for Hematologic Malignancies.
  • Celgene reportedly in talks to buy CAR-T cell therapy firm.

 

 

Market Segmentation

 

Hematologic Malignancies Market by Disease Type (Revenue, Million, 2014 – 2025)

  • Leukemia
    • Acute Lymphocytic Leukemia
    • Chronic Lymphocytic Leukemia
    • Acute Myeloid Leukemia
    • Chronic Myeloid Leukemia
  • Non-Hodgkin Lymphoma
    • B-cell Lymphoma
      • Diffuse Large B-Cell Lymphoma
      • Mantle Cell Lymphoma
      • Burkitt Lymphoma
      • Central Nervous System Lymphoma
    • T-cell Lymphoma
      • Precursor T-Lymphoblastic Lymphoma
      • Peripheral T-Lymphoma
    • Hodgkin Lymphoma
    • Multiple Myeloma

 

Hematologic Malignancies Market by Treatment Categories (Revenue, Million, 2014 – 2025)

  • Chemotherapy
  • Radiation therapy
  • Immunotherapy
  • Stem Cell Transplantation

 

Hematologic Malignancies Market by Drug Class (Revenue, Million, 2014 – 2025)

  • Antineoplastic agent (Glivec, Revlimid (Lenalidomide), Pomalyst (Pomalidomide) Vidaza (Azacitidine) Kyprolis (Carfilzomib) Adcetris (Brentuximab Vedotin))
  • Chemotherapy (Velcade (Bortezomib)
  • Kinase Inhibitor (Tasigna (Nilotinib))

 

Hematologic Malignancies Market by Distribution Channel (Revenue, Million, 2014 – 2025)

  • Hospitals
  • Drug Store
  • Specialty Pharmacy
  • E-Pharmacy

 

Hematologic Malignancies Market Regional Outlook (Revenue, USD Million, 2014- 2025)

 

  • North America
    • U.S.
    • Canada
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
  • Asia Pacific
    • Japan
    • China
    • India
  • Latin America
    • Brazil
    • Mexico
    • Columbia
  • Middle East and Africa
    • South Africa
    • Saudi Arabia

 

Hematologic Malignancies Market, Hematologic Malignancies Market Analytics, Hematologic Malignancies Market Share, Hematologic Malignancies Market Research, Hematologic Malignancies Market Forecast, Hematologic Malignancies Market Insight, Hematologic Malignancies Market Trend, Hematologic Malignancies Market Value,Hematologic Malignancies Market Size, Hematologic Malignancies Market Analysis, Hematologic Malignancies Market Survey, Blood Cancer Drugs Market, Blood Cancer Drugs Market Analytics, Blood Cancer Drugs Market Share, Blood Cancer Drugs Market Research, Blood Cancer Drugs Market Forecast, Blood Cancer Drugs Market Insight, Blood Cancer Drugs Market Trend, Blood Cancer Drugs Market Value,Blood Cancer Drugs Market Size, Blood Cancer Drugs Market Analysis, Blood Cancer Drugs Market Survey

Additional information

Price

Single User $3,650, Multiple User $4,650, Enterprise User $6650